ArticleScientific reports2025
Curcumin's dual effect on pyroptosis and autophagy in metabolic- associated fatty liver disease: a potential therapeutic strategy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting pyroptosis in metabolic dysfunction-associated steatotic liver disease: from molecular mechanisms to therapeutic innovation.Molecular biology reports · 2026Review
- Comparative Efficacy of Herbal Products for Improving Liver Enzymes and Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis.Gastro hep advances · 2026Review
- Precision nutrition for NAFLD: a mechanistic rationale for targeting the cytokine landscape.Frontiers in cell and developmental biology · 2026Review
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic-associated fatty liver disease (MAFLD) has become a considerable public health concern due to its elevated prevalence and its probability of progressing into hepatocellular carcinoma. Autophagy and pyroptosis are key cellular processes involved in MAFLD progression, with autophagy acting as a protective mechanism by inhibiting inflammasome activation. At the same time, excessive pyroptosis contributes to inflammation and tissue damage. Gasdermin D (GSDMD), a key executor of pyroptosis, plays a central role in this process by mediating inflammatory cell death and has emerged as a potential marker of liver injury severity. This study evaluates curcumin's effects on liver fat accumulation, inflammatory cytokine levels, oxidative stress, and its potential to regulate autophagy and pyroptosis. Rats were allocated to three groups. Group I established a normal diet for twelve weeks. Group II was given a high-fat, high-fructose diet (HFFD) for twelve weeks. Group III received the HFFD diet for twelve weeks with curcumin supplementation from the 6th to the 12th week. Rats in Group III showed significant improvements in adiposity, lipid metabolism, oxidative stress, and inflammatory markers. Histopathological analysis confirmed the beneficial effects of curcumin, with notable improvements in liver structure and reduced Lipid-associated liver dysfunction severity. Furthermore, curcumin's dual effects on autophagy through modulation of P62 protein and BECN1 gene and on pyroptosis through inhibition of GSDMD activation, were evident, supporting its protective role in preventing MAFLD progression to fibrosis and liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.